Orlistat and weight loss program for gout with obesity
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests whether the weight loss drug orlistat, combined with weight management, can help lower uric acid levels in people who have both gout and obesity. If you join, you will take orlistat and receive guidance on healthy eating and activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with gout by a doctor.
- Your BMI is 28 or higher (meaning you have obesity).
- Your uric acid level is 480 μmol/L or more (high).
- You are willing to follow the study plan and take the medication as directed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines—metformin (usually for diabetes) and febuxostat (for gout)—in people who have both gout and obesity but not diabetes. The goal is to see which works better for controlling gout and related health markers.
This trial tests a new medicine called tigulixostat against febuxostat, a standard gout treatment, to see which works better at lowering uric acid levels. You may qualify if you have gout with high uric acid and have not had a gout flare in the last month.
This study compares two different treatment goals for a blood level called urate in people with gout. The goal is to see which approach lowers gout flares better while helping people feel better.
This trial tests if gradually lowering the dose of the gout medication febuxostat is safe for people whose gout has been well-controlled for at least 5 years. The goal is to see if a lower dose can still keep uric acid levels in a healthy range.
This study tests whether a pharmacist-led program can help veterans with gout better manage their uric acid levels using common medications like allopurinol or febuxostat. If you have had a gout flare in the last 6 months and are already taking or starting a urate-lowering medication, this trial may be for you.
This trial tests an experimental tablet (SHR4640) added to the standard gout medicine febuxostat (40 mg daily) for people whose uric acid remains too high despite febuxostat alone. The goal is to see if the combination lowers uric acid more effectively and safely.
Hear when a new Gout trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.